Michael Makris/LinkedIn
Feb 25, 2026, 16:34
Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”IMPORTANT.
Biomarin has decided to withdraw Roctavian, the only approved Haemophilia A gene therapy, from the market.
Biomarin announced several months ago that it wanted to sell Roctavian to another company, but since they failed to find a buyer, they made the decision to voluntarily withdraw Roctavian from the market.
The problem was not that this did not work, but rather that there are a lot of other highly effective choices for haemophilia A subjects available.”
Stay updated with Hemostasis Today.
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center
-
May 29, 2026, 17:20Martin Widschwendter: How Molecular Detection Tests Could Transform Endometrial Cancer Care
-
May 29, 2026, 17:18Nina Lansbury: Supporting a Period Friendly World With Menstrual Health Research and Education
-
May 29, 2026, 17:16Ipsita Chatterjee: Red is Not Shame, Red is Power, Red is a Woman
-
May 29, 2026, 16:49Abdulrahman Nasiri: The Evolving Role of Romiplostim in SAA
-
May 29, 2026, 16:46Soumen Bhattacharya: UC-II and Immune Modulation in Osteoarthritis
-
May 29, 2026, 16:38Ana Pedrero Gil: Red Blood Cell Transfusion Practice in Spain – High Inappropriateness Despite Low Overall Use
-
May 29, 2026, 15:40Lena Volland: Expanding Holistic Care in Bleeding Disorders Through Pelvic Health Physical Therapy at WFH Congress